How do you counsel eligible patients on how to decide between lecanemab vs donanemab?  

Donanemab is not yet offered at my institution, though we expect it to be soon. With that caveat, it is my view that lecanemab will almost always be my recommendation because of the lower rate of ARIA, especially in e4 carriers. While the Q4W dosing regimen of donanemab is an attractive feature for ...

I counsel patients that there is no difference between the two drugs with regards to efficacy or safety. I do not have a preference for one or the other.

UVA is not yet offering donanemab so most patients are opting to start lecanemab which is readily available. Only a few patients decided to wait. I do not favor one over the other. We discuss the information available. Donanemab has the advantage of infusions once every 4 weeks compared to lecanemab...